Ardelyx, Inc. (ARDX)
์๊ฐ์ด์ก: 1.30B
๊ตญ๊ฐ: United States
์ฐ์ : #Biotechnology_Pharmaceutical_Preparations
์นํฐ: #Health_Care
ํํ์ด์ง: https://www.ardelyx.com
- ๋ถ๊ธฐ ๋งค์ถ(๊ณต์, ์์ธก, ์ํ, YoY, MoM)
2406: 73.2M / 55.03M / 33.0% / 227.8% / 59.1%
2403: 46.02M / -- / -- / 304.8% / 33.9%
2312: 34.36M / -- / -- / -- / -39.1%
2309: 56.39M / -- / -- / -- / 152.5%
2306: 22.33M / -- / -- / -- / 96.4%
- ๋ถ๊ธฐ EPS(๊ณต์, ์์ธก, ์ํ, YoY, MoM)
2406: -0.07 / -0.11 / 36.4% / 12.5% / 36.4%
2403: -0.11 / -- / -- / 15.4% / --
2312: -- / -- / -- / -- / --
2309: 0.03 / -- / -- / -- / 137.5%
2306: -0.08 / -- / -- / -- / 38.5%
- ์ฐ๊ฐ ๋งค์ถ(YoY%), EPS(YoY%)
2312: 124.46M(138.6%) / -0.3(28.6%)
2212: 52.16M(416.6%) / -0.42(72.4%)
2112: 10.1M(33.4%) / -1.52(-44.8%)
2012: 7.57M(--) / -1.05(--)
#ARDX
- ์ฌ์ ์์ฝ: Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor f...
์๊ฐ์ด์ก: 1.30B
๊ตญ๊ฐ: United States
์ฐ์ : #Biotechnology_Pharmaceutical_Preparations
์นํฐ: #Health_Care
ํํ์ด์ง: https://www.ardelyx.com
- ๋ถ๊ธฐ ๋งค์ถ(๊ณต์, ์์ธก, ์ํ, YoY, MoM)
2406: 73.2M / 55.03M / 33.0% / 227.8% / 59.1%
2403: 46.02M / -- / -- / 304.8% / 33.9%
2312: 34.36M / -- / -- / -- / -39.1%
2309: 56.39M / -- / -- / -- / 152.5%
2306: 22.33M / -- / -- / -- / 96.4%
- ๋ถ๊ธฐ EPS(๊ณต์, ์์ธก, ์ํ, YoY, MoM)
2406: -0.07 / -0.11 / 36.4% / 12.5% / 36.4%
2403: -0.11 / -- / -- / 15.4% / --
2312: -- / -- / -- / -- / --
2309: 0.03 / -- / -- / -- / 137.5%
2306: -0.08 / -- / -- / -- / 38.5%
- ์ฐ๊ฐ ๋งค์ถ(YoY%), EPS(YoY%)
2312: 124.46M(138.6%) / -0.3(28.6%)
2212: 52.16M(416.6%) / -0.42(72.4%)
2112: 10.1M(33.4%) / -1.52(-44.8%)
2012: 7.57M(--) / -1.05(--)
#ARDX
- ์ฌ์ ์์ฝ: Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor f...
#ARDX
Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update
https://finance.yahoo.com/news/ardelyx-reports-second-quarter-2024-200100472.html
Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAHยฎ (tenapanor) Clinical Trials in Current Medical Research and Opinion
https://finance.yahoo.com/news/ardelyx-announces-publication-two-plain-120200775.html
Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
https://finance.yahoo.com/news/biocryst-pharmaceuticals-bcrx-report-negative-140042779.html
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?
https://finance.yahoo.com/news/ardelyx-ardx-expected-beat-earnings-140153169.html
Ardelyx sues CMS over revamped kidney disease drug payment bundle
https://finance.yahoo.com/m/70e266c0-2da7-3790-bac2-a99ace9400d7/ardelyx-sues-cms-over.html
Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update
https://finance.yahoo.com/news/ardelyx-reports-second-quarter-2024-200100472.html
Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAHยฎ (tenapanor) Clinical Trials in Current Medical Research and Opinion
https://finance.yahoo.com/news/ardelyx-announces-publication-two-plain-120200775.html
Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
https://finance.yahoo.com/news/biocryst-pharmaceuticals-bcrx-report-negative-140042779.html
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?
https://finance.yahoo.com/news/ardelyx-ardx-expected-beat-earnings-140153169.html
Ardelyx sues CMS over revamped kidney disease drug payment bundle
https://finance.yahoo.com/m/70e266c0-2da7-3790-bac2-a99ace9400d7/ardelyx-sues-cms-over.html
Yahoo Finance
Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update
IBSRELA generates $35.4 million in net product sales revenue XPHOZAH generates $37.1 million in net product sales revenue Company ends Q2 with approximately $186 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass.โฆ
Ardelyx, Inc. (ARDX)
์๊ฐ์ด์ก: 1.39B
๊ตญ๊ฐ: United States
์ฐ์ : #Biotechnology_Pharmaceutical_Preparations
์นํฐ: #Health_Care
ํํ์ด์ง: https://www.ardelyx.com
- ๋ถ๊ธฐ ๋งค์ถ(๊ณต์, ์์ธก, ์ํ, YoY, QoQ)
2409: 98.2M / 86.64M / 13.3% / 74.1% / 34.2%
2406: 73.2M / 55.03M / 33.0% / 227.8% / 59.1%
2403: 46.02M / -- / -- / 304.8% / 33.9%
2312: 34.36M / -- / -- / -- / -39.1%
2309: 56.39M / -- / -- / -- / 152.5%
- ๋ถ๊ธฐ EPS(๊ณต์, ์์ธก, ์ํ, YoY, QoQ)
2409: 0.0 / -0.05 / 100.0% / -100.0% / 100.0%
2406: -0.07 / -0.11 / 36.4% / 12.5% / 36.4%
2403: -0.11 / -- / -- / 15.4% / --
2312: -- / -- / -- / -- / --
2309: 0.03 / -- / -- / -- / 137.5%
- ์ฐ๊ฐ ๋งค์ถ(YoY%), EPS(YoY%)
2312: 124.46M(138.6%) / -0.3(28.6%)
2212: 52.16M(416.6%) / -0.42(72.4%)
2112: 10.1M(33.4%) / -1.52(-44.8%)
2012: 7.57M(--) / -1.05(--)
#ARDX
- ์ฌ์ ์์ฝ: Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product cand...
์๊ฐ์ด์ก: 1.39B
๊ตญ๊ฐ: United States
์ฐ์ : #Biotechnology_Pharmaceutical_Preparations
์นํฐ: #Health_Care
ํํ์ด์ง: https://www.ardelyx.com
- ๋ถ๊ธฐ ๋งค์ถ(๊ณต์, ์์ธก, ์ํ, YoY, QoQ)
2409: 98.2M / 86.64M / 13.3% / 74.1% / 34.2%
2406: 73.2M / 55.03M / 33.0% / 227.8% / 59.1%
2403: 46.02M / -- / -- / 304.8% / 33.9%
2312: 34.36M / -- / -- / -- / -39.1%
2309: 56.39M / -- / -- / -- / 152.5%
- ๋ถ๊ธฐ EPS(๊ณต์, ์์ธก, ์ํ, YoY, QoQ)
2409: 0.0 / -0.05 / 100.0% / -100.0% / 100.0%
2406: -0.07 / -0.11 / 36.4% / 12.5% / 36.4%
2403: -0.11 / -- / -- / 15.4% / --
2312: -- / -- / -- / -- / --
2309: 0.03 / -- / -- / -- / 137.5%
- ์ฐ๊ฐ ๋งค์ถ(YoY%), EPS(YoY%)
2312: 124.46M(138.6%) / -0.3(28.6%)
2212: 52.16M(416.6%) / -0.42(72.4%)
2112: 10.1M(33.4%) / -1.52(-44.8%)
2012: 7.57M(--) / -1.05(--)
#ARDX
- ์ฌ์ ์์ฝ: Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product cand...
#ARDX
Compared to Estimates, Ardelyx (ARDX) Q3 Earnings: A Look at Key Metrics
https://finance.yahoo.com/news/compared-estimates-ardelyx-ardx-q3-213006937.html
Ardelyx (ARDX) Reports Break-Even Earnings for Q3
https://finance.yahoo.com/news/ardelyx-ardx-reports-break-even-211514861.html
Ardelyx: Q3 Earnings Snapshot
https://finance.yahoo.com/news/ardelyx-q3-earnings-snapshot-202220676.html
Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update
https://finance.yahoo.com/news/ardelyx-reports-third-quarter-2024-200200085.html
Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterologyโs (ACG) Annual Meeting
https://finance.yahoo.com/news/ardelyx-presents-results-ibs-america-200500219.html
Compared to Estimates, Ardelyx (ARDX) Q3 Earnings: A Look at Key Metrics
https://finance.yahoo.com/news/compared-estimates-ardelyx-ardx-q3-213006937.html
Ardelyx (ARDX) Reports Break-Even Earnings for Q3
https://finance.yahoo.com/news/ardelyx-ardx-reports-break-even-211514861.html
Ardelyx: Q3 Earnings Snapshot
https://finance.yahoo.com/news/ardelyx-q3-earnings-snapshot-202220676.html
Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update
https://finance.yahoo.com/news/ardelyx-reports-third-quarter-2024-200200085.html
Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterologyโs (ACG) Annual Meeting
https://finance.yahoo.com/news/ardelyx-presents-results-ibs-america-200500219.html
Yahoo
Compared to Estimates, Ardelyx (ARDX) Q3 Earnings: A Look at Key Metrics
The headline numbers for Ardelyx (ARDX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
11์ 1์ผ ๊ธ์์ผ ๊ฐ์ด๋์ค ์ํฅ ๊ธฐ์
์ ๋ฆฌ
1. Peloton Interactive, Inc. (#PTON)
- ๊ตฌ๋ ์ ์ฑ์ฅ๊ณผ ํ๋ซํผ ํ์ฅ ๋ชฉํ
2. Travere Therapeutics, Inc. (#TVTX)
- IgAN ์น๋ฃ์ ๋ก ์ฑ์ฅ ์ค
3. IDACORP, Inc. (#IDA)
- ๊ณ ๊ฐ ์ฆ๊ฐ ๋ฐ ์์จ ์กฐ์ ์ด์ต
4. Itron, Inc. (#ITRI)
- 3๋ถ๊ธฐ ์ด์ ๋ชจ๋ฉํ ์ ์ง ์ฑ๊ณผ
5. Bristol Myers Squibb (#BMY)
- ์ฃผ์ ํ์ดํ๋ผ์ธ ์ง์ ๊ณผ ํ๊ธ ํ๋ฆ
6. Leonardo DRS (#DRS)
- ํด์ ๋ ์ด๋ ๊ณ์ฝ ์ฑ์ฅ ๋ชฉํ
7. Trane Technologies (#TT)
- ์์ ์ฉ HVAC ์ง์ ์ฑ์ฅ ๊ธฐ๋
8. OneSpaWorld Holdings (#OSW)
- ํฌ์ค ์ฐ๋์ค ์๋น์ค ์ฑ์ฅ ํ๋
9. Kadant Inc. (#KAI)
- ์์์ ํจ์จ์ ์ด์ ์ต๊ณ ์ค์
10. Brinker International (#EAT)
- Chiliโs ๋งค์ถ ์ฑ์ฅ๋ฅ ์ฆ๊ฐ
11. Norwegian Cruise Line (#NCLH)
- ๋งค์ถ, ์์ด์ต, EBITDA ๊ธฐ๋ก์ ์ฑ์ฅ
12. Ametek Inc. (#AME)
- AI ์์ฅ ์ฑ์ฅ ์ํ ๊ธฐ๋
13. Exelixis Inc. (#EXEL)
- CABOMETYX ํ๋งค ์ง์ ์ฑ์ฅ
14. Rush Street Interactive (#RSI)
- ๋งค์ถ๊ณผ EBITDA ์ฐ์ ์ฆ๊ฐ
15. Weave Communications (#WEAV)
- ๊ณ ๊ฐ ๊ฒฝํ ๊ฐ์ ๊ณผ ์ฑ์ฅ์ด ๋ชฉํ
16. GoDaddy Inc. (#GDDY)
- Airo ํ๋ซํผ ํ์ฅ ๊ณํ ๋ฐํ
17. ONEOK, Inc. (#OKE)
- ์ฌ์ ์๋์ง ์ฑ๊ณผ์ ์์ต ์ฐฝ์ถ ๊ธฐ๋
18. Amazon.com, Inc. (#AMZN)
- AI ํฌ์ ํ๋์ ์๋ก์ด ์๋น์ค ์ถ์
19. Apple Inc. (#AAPL)
- AI ๊ธฐ๋ฅ ์ถ์ ์ ์ค ์ ๊ทผ
20. Corcept Therapeutics (#CORT)
- ์ ํ ์ฑ์ฅ๊ณผ ์ฌ๋ฌด ๊ตฌ์กฐ ๊ฐํ
21. Cadence Design Systems (#CDNS)
- AI ์นฉ ์ค๊ณ ์์ ์ฆ๊ฐ ์ ๋ง
22. Halozyme Therapeutics (#HALO)
- ๊ฐ๋ ฅํ ์ฑ๊ณผ์ ํ์ดํ๋ผ์ธ ํ์ฅ ๊ธฐ๋
23. ChromaDex Corporation (#CDXC)
- Niagen+ ์ ํ ํ๋ ๊ณํ
24. ICF International (#ICFI)
- ์๋์ง ํจ์จ ๋ฐ ์์ ์ฆ๊ฐ ์ ๋ง
25. Grid Dynamics Holdings (#GDYN)
- AI ์๋ฃจ์ ์์ ์ฆ๊ฐ ์์
26. Avis Budget Group (#CAR)
- ๋น์ฉ ์ ๊ฐ๊ณผ ์ฐจ๋ ์ต์ ํ ์ ๋ต
27. Ingersoll Rand (#IR)
- ์ฅ๊ธฐ ์ฑ์ฅ ๋ชฉํ์ ์๋ณธ ํฌ์
28. AES Corporation (#AES)
- ์ฌ์ ์๋์ง ๋ฐ ๋ฐ์ดํฐ ์์ ์ฑ์ฅ
29. MasTec, Inc. (#MTZ)
- ๋งค์ถ ์ฆ๊ฐ์ ๋ฐฑ๋ก๊ทธ ๊ฐ๋ ฅ ๊ธฐ๋
30. Sonoco Products Company (#SON)
- ํฌ์ฅ ์์ ์ฆ๊ฐ์ ์ด์ต๋ฅ ๊ฐ์
31. Dorman Products, Inc. (#DORM)
- ์์๋ณด๋ค ๋์ ์์ต ์ฑ์ฅ ๋ฌ์ฑ
32. Ardelyx, Inc. (#ARDX)
- IBSRELA, XPHOZAH ์ฑ๊ณผ ์ง์
33. Curtiss-Wright Corporation (#CW)
- ํญ๊ณต์ฐ์ฃผ ์์ ๋ฐ ์ฃผ๋ฌธ ์ฆ๊ฐ
34. Interface, Inc. (#TILE)
- ์ ๋ต ํตํด ์์ต์ฑ ์ฆ๊ฐ ๊ธฐ๋
35. AdvanSix Inc. (#ASIX)
- ๋ค์ํ ์ ํ ํฌํธํด๋ฆฌ์ค๋ก ์ฑ์ฅ
36. Butterfly Network, Inc. (#BFLY)
- ์ ๋ต์ ์ฑ์ฅ๊ณผ ์ผ๊ด๋ ์ฑ๊ณผ ๊ฐ์กฐ
37. Cardinal Health, Inc. (#CAH)
- ์ด์ ๊ฐ์ ์ผ๋ก ํ๊ณ์ฐ๋ ์ ๋ง ์ํฅ
38. Charter Communications, Inc. (#CHTR)
- ๊ณ ๊ฐ ๊ฐ์น์ ๊ฒฝ์ ์ฐ์ ํ๋ณด
39. Dominion Energy, Inc. (#D)
- ์์ ๊ด๋ฆฌ์ ๊ณ ๊ฐ ๋น์ฉ ํจ์จ์ฑ
https://naver.me/xLWhhPKJ
1. Peloton Interactive, Inc. (#PTON)
- ๊ตฌ๋ ์ ์ฑ์ฅ๊ณผ ํ๋ซํผ ํ์ฅ ๋ชฉํ
2. Travere Therapeutics, Inc. (#TVTX)
- IgAN ์น๋ฃ์ ๋ก ์ฑ์ฅ ์ค
3. IDACORP, Inc. (#IDA)
- ๊ณ ๊ฐ ์ฆ๊ฐ ๋ฐ ์์จ ์กฐ์ ์ด์ต
4. Itron, Inc. (#ITRI)
- 3๋ถ๊ธฐ ์ด์ ๋ชจ๋ฉํ ์ ์ง ์ฑ๊ณผ
5. Bristol Myers Squibb (#BMY)
- ์ฃผ์ ํ์ดํ๋ผ์ธ ์ง์ ๊ณผ ํ๊ธ ํ๋ฆ
6. Leonardo DRS (#DRS)
- ํด์ ๋ ์ด๋ ๊ณ์ฝ ์ฑ์ฅ ๋ชฉํ
7. Trane Technologies (#TT)
- ์์ ์ฉ HVAC ์ง์ ์ฑ์ฅ ๊ธฐ๋
8. OneSpaWorld Holdings (#OSW)
- ํฌ์ค ์ฐ๋์ค ์๋น์ค ์ฑ์ฅ ํ๋
9. Kadant Inc. (#KAI)
- ์์์ ํจ์จ์ ์ด์ ์ต๊ณ ์ค์
10. Brinker International (#EAT)
- Chiliโs ๋งค์ถ ์ฑ์ฅ๋ฅ ์ฆ๊ฐ
11. Norwegian Cruise Line (#NCLH)
- ๋งค์ถ, ์์ด์ต, EBITDA ๊ธฐ๋ก์ ์ฑ์ฅ
12. Ametek Inc. (#AME)
- AI ์์ฅ ์ฑ์ฅ ์ํ ๊ธฐ๋
13. Exelixis Inc. (#EXEL)
- CABOMETYX ํ๋งค ์ง์ ์ฑ์ฅ
14. Rush Street Interactive (#RSI)
- ๋งค์ถ๊ณผ EBITDA ์ฐ์ ์ฆ๊ฐ
15. Weave Communications (#WEAV)
- ๊ณ ๊ฐ ๊ฒฝํ ๊ฐ์ ๊ณผ ์ฑ์ฅ์ด ๋ชฉํ
16. GoDaddy Inc. (#GDDY)
- Airo ํ๋ซํผ ํ์ฅ ๊ณํ ๋ฐํ
17. ONEOK, Inc. (#OKE)
- ์ฌ์ ์๋์ง ์ฑ๊ณผ์ ์์ต ์ฐฝ์ถ ๊ธฐ๋
18. Amazon.com, Inc. (#AMZN)
- AI ํฌ์ ํ๋์ ์๋ก์ด ์๋น์ค ์ถ์
19. Apple Inc. (#AAPL)
- AI ๊ธฐ๋ฅ ์ถ์ ์ ์ค ์ ๊ทผ
20. Corcept Therapeutics (#CORT)
- ์ ํ ์ฑ์ฅ๊ณผ ์ฌ๋ฌด ๊ตฌ์กฐ ๊ฐํ
21. Cadence Design Systems (#CDNS)
- AI ์นฉ ์ค๊ณ ์์ ์ฆ๊ฐ ์ ๋ง
22. Halozyme Therapeutics (#HALO)
- ๊ฐ๋ ฅํ ์ฑ๊ณผ์ ํ์ดํ๋ผ์ธ ํ์ฅ ๊ธฐ๋
23. ChromaDex Corporation (#CDXC)
- Niagen+ ์ ํ ํ๋ ๊ณํ
24. ICF International (#ICFI)
- ์๋์ง ํจ์จ ๋ฐ ์์ ์ฆ๊ฐ ์ ๋ง
25. Grid Dynamics Holdings (#GDYN)
- AI ์๋ฃจ์ ์์ ์ฆ๊ฐ ์์
26. Avis Budget Group (#CAR)
- ๋น์ฉ ์ ๊ฐ๊ณผ ์ฐจ๋ ์ต์ ํ ์ ๋ต
27. Ingersoll Rand (#IR)
- ์ฅ๊ธฐ ์ฑ์ฅ ๋ชฉํ์ ์๋ณธ ํฌ์
28. AES Corporation (#AES)
- ์ฌ์ ์๋์ง ๋ฐ ๋ฐ์ดํฐ ์์ ์ฑ์ฅ
29. MasTec, Inc. (#MTZ)
- ๋งค์ถ ์ฆ๊ฐ์ ๋ฐฑ๋ก๊ทธ ๊ฐ๋ ฅ ๊ธฐ๋
30. Sonoco Products Company (#SON)
- ํฌ์ฅ ์์ ์ฆ๊ฐ์ ์ด์ต๋ฅ ๊ฐ์
31. Dorman Products, Inc. (#DORM)
- ์์๋ณด๋ค ๋์ ์์ต ์ฑ์ฅ ๋ฌ์ฑ
32. Ardelyx, Inc. (#ARDX)
- IBSRELA, XPHOZAH ์ฑ๊ณผ ์ง์
33. Curtiss-Wright Corporation (#CW)
- ํญ๊ณต์ฐ์ฃผ ์์ ๋ฐ ์ฃผ๋ฌธ ์ฆ๊ฐ
34. Interface, Inc. (#TILE)
- ์ ๋ต ํตํด ์์ต์ฑ ์ฆ๊ฐ ๊ธฐ๋
35. AdvanSix Inc. (#ASIX)
- ๋ค์ํ ์ ํ ํฌํธํด๋ฆฌ์ค๋ก ์ฑ์ฅ
36. Butterfly Network, Inc. (#BFLY)
- ์ ๋ต์ ์ฑ์ฅ๊ณผ ์ผ๊ด๋ ์ฑ๊ณผ ๊ฐ์กฐ
37. Cardinal Health, Inc. (#CAH)
- ์ด์ ๊ฐ์ ์ผ๋ก ํ๊ณ์ฐ๋ ์ ๋ง ์ํฅ
38. Charter Communications, Inc. (#CHTR)
- ๊ณ ๊ฐ ๊ฐ์น์ ๊ฒฝ์ ์ฐ์ ํ๋ณด
39. Dominion Energy, Inc. (#D)
- ์์ ๊ด๋ฆฌ์ ๊ณ ๊ฐ ๋น์ฉ ํจ์จ์ฑ
https://naver.me/xLWhhPKJ
Naver
US ์ค์ ๊ฐ์ ๊ธฐ์
์์ฝ
Forwarded from TNBfolio
[24๋
11์ 11์ผ]
1. ํด์ธ ๋ด์ค
๊ฐ) ๋ด์ค ์คํฌ๋ฉ
- Fed Kashkari, ์ด๋ฏผ์ ์ถ๋ฐฉ ๊ฒฝ์ ์ฐ๋ ค
- Moody's, ๋ฏธ๊ตญ ์ ์ฉ ๋ฆฌ์คํฌ ๊ฒฝ๊ณ
- ํธ๋ผํ ๋น์ , ์์์ ๊ด์ธ ๊ฐ๋ฅ์ฑ ์์น
- ํธ๋ผํ, ์ค๊ตญ์ฐ ์ ํ ์ถ๊ฐ ๊ด์ธ
- Pangestu, ์ค๊ตญ ๊ณต๊ธ๋ง ๋ณดํธ์กฐ์น ์์
- Steve Sosnick, ๊ณตํ๋น ์์ฅ ์ฐํธ์ ๊ธฐ๋
- Sonal Desai, ๊ท์ ์ํ ์ธํ๋ ์ด์ ์ํ
- Bannister, S&P 500 ํ๋ฝ ๊ฐ๋ฅ์ฑ
- Luzzetti, ํธ๋ผํ ์ ์ฑ ๋ฌผ๊ฐ ์์น ์์
- Woodring, ์ค๊ตญ ๊ด์ธ ํ๋์จ์ด ์ฃผ ํ๊ฒฉ
- Roubini, ํธ๋ผํ ์ ์ฑ ๊ฒฝ์ ์ํ์ฑ
- Gartman, ํธ๋ผํ ์ ์ฑ ์ฌ์ ๋ถ๋ด ์ฐ๋ ค
- ์ฐ๋ฐฉ ์์ฐ ์์ํ, ๋ถ์ฑ ์ฆ๊ฐ ์์
https://naver.me/xrS92okL
2. US ๊ธฐ์ TP ์ ๋ฆฌ
๊ฐ) ๋ฑ๊ธ ์ํฅ
#AKAM, #AMH, #CBOE, #CSCO, #EPAM, #MLNK, #MRCY, #NTST, #OEC, #OUST, #PINS, #SKT, #UEIC, #UPST, #VLY, #WBD, #WGO, #TSLA, #ANET, #BMY, #ETN, #GEN, #G, #ITW, #IR, #JCI, #NVT, #OTIS, #PH, #TT, #USFD, #VRT, #WSO
๋) ํฌ์ ๋ฑ๊ธ ํํฅ
#AGL, #ALTM, #ARDX, #ATMU, #BLMN, #CBT, #CE, #GCMG, #IMCR, #MRK, #NOV, #NRDY, #NVR, #PRA, #RVTY, #SMAR, #TDW, #TEM, #VALE, #WHF, #XERS, #AKAM, #CVS, #FLR, #MRNA, #REGN
https://naver.me/xrS92okL
3. ํ๊ตญ ์ ๋ ๋ด์ค (์ ์ฒด ๊ณต๊ฐ)
* ์ฃผ์ ๋ด์ฉ
๊ด๊ตฐ์ ํ ์ธ ์ฌ๋ ฅ ๋ถ์กฑ, ๋์ฟ์ฆ์ ๋ณดํฉ์ธ, ์ค๊ตญ ๋ฐ๋์ฒด ๋งค์์ธ
MBK ์ํ, ๊ณ ๋ ค์์ฐ ์ง๋ถ ์ถ๊ฐ
๋ฐ๋์ฒด็คพ ๋ฐฐํฐ๋ฆฌ็คพ ์ธ์ ๋ ผ๋, ์ผ๋ณธ ๋ฐ๋์ฒด AI ๋ณด์กฐ๊ธ
ํ๋์ฐจ ์ค๊ตญ ์์จ์ฃผํ ํ๋ ฅ
๋ง์ดํฌ๋ก์คํธ๋ํฐ์ง ๋นํธ์ฝ์ธ ๋๊ท๋ชจ ๋งค์
ํ๊ตญ ์๋ฃAI ๋ฏธ๊ตญ ๋์ , K๋ฐ์ด์ค ๋งค์ถ ๋ฏธ๋ฌ, ๋ฉ๋ํก์ค ์ ๋ฝ ํธ์กฐ, ์คํ๋ก ๋ฐ์ด์ค ์ ๋ฝ ๊ธฐ์ ์ด์
๋์ด ์ ์ฃผ ์๋๊ณ ์ถ๊ฐ ๋น์ฉ
https://naver.me/Fnm9lu8Z
* ํด์ธ ์ํฉ์ ๋งค์ผ ์์นจ ํ๋ฆฌ๋ฏธ์ ์ปจํ ์ธ ๋ฅผ ํตํด ํผ๋ฉ ๋๋ฆฌ๊ณ ์์ต๋๋ค.
* TNBfolio ๋ค์ด๋ฒ ์ปจํ ์ธ ํ๋ฆฌ๋ฏธ์์์ ์ ๊ณตํ๋ ์๋ฃ์ด๋ฉฐ ๋ ์๋ฃ๋ ๊ณ ๊ฐ์ ์ฆ๊ถ ํฌ์ ๊ฒฐ๊ณผ์ ๋ํ ๋ฒ์ ์ฑ ์์์ฌ์ ์ฆ๋น์๋ฃ๋ก ์ฌ์ฉ๋ ์ ์์ต๋๋ค.
๋งํฌ๋ฅผ ํด๋ฆญ ํ์๋ฉด ๊ตฌ๋ ์ ์ฒญ ํ์ค ์ ์์ต๋๋ค.
1. ํด์ธ ๋ด์ค
๊ฐ) ๋ด์ค ์คํฌ๋ฉ
- Fed Kashkari, ์ด๋ฏผ์ ์ถ๋ฐฉ ๊ฒฝ์ ์ฐ๋ ค
- Moody's, ๋ฏธ๊ตญ ์ ์ฉ ๋ฆฌ์คํฌ ๊ฒฝ๊ณ
- ํธ๋ผํ ๋น์ , ์์์ ๊ด์ธ ๊ฐ๋ฅ์ฑ ์์น
- ํธ๋ผํ, ์ค๊ตญ์ฐ ์ ํ ์ถ๊ฐ ๊ด์ธ
- Pangestu, ์ค๊ตญ ๊ณต๊ธ๋ง ๋ณดํธ์กฐ์น ์์
- Steve Sosnick, ๊ณตํ๋น ์์ฅ ์ฐํธ์ ๊ธฐ๋
- Sonal Desai, ๊ท์ ์ํ ์ธํ๋ ์ด์ ์ํ
- Bannister, S&P 500 ํ๋ฝ ๊ฐ๋ฅ์ฑ
- Luzzetti, ํธ๋ผํ ์ ์ฑ ๋ฌผ๊ฐ ์์น ์์
- Woodring, ์ค๊ตญ ๊ด์ธ ํ๋์จ์ด ์ฃผ ํ๊ฒฉ
- Roubini, ํธ๋ผํ ์ ์ฑ ๊ฒฝ์ ์ํ์ฑ
- Gartman, ํธ๋ผํ ์ ์ฑ ์ฌ์ ๋ถ๋ด ์ฐ๋ ค
- ์ฐ๋ฐฉ ์์ฐ ์์ํ, ๋ถ์ฑ ์ฆ๊ฐ ์์
https://naver.me/xrS92okL
2. US ๊ธฐ์ TP ์ ๋ฆฌ
๊ฐ) ๋ฑ๊ธ ์ํฅ
#AKAM, #AMH, #CBOE, #CSCO, #EPAM, #MLNK, #MRCY, #NTST, #OEC, #OUST, #PINS, #SKT, #UEIC, #UPST, #VLY, #WBD, #WGO, #TSLA, #ANET, #BMY, #ETN, #GEN, #G, #ITW, #IR, #JCI, #NVT, #OTIS, #PH, #TT, #USFD, #VRT, #WSO
๋) ํฌ์ ๋ฑ๊ธ ํํฅ
#AGL, #ALTM, #ARDX, #ATMU, #BLMN, #CBT, #CE, #GCMG, #IMCR, #MRK, #NOV, #NRDY, #NVR, #PRA, #RVTY, #SMAR, #TDW, #TEM, #VALE, #WHF, #XERS, #AKAM, #CVS, #FLR, #MRNA, #REGN
https://naver.me/xrS92okL
3. ํ๊ตญ ์ ๋ ๋ด์ค (์ ์ฒด ๊ณต๊ฐ)
* ์ฃผ์ ๋ด์ฉ
๊ด๊ตฐ์ ํ ์ธ ์ฌ๋ ฅ ๋ถ์กฑ, ๋์ฟ์ฆ์ ๋ณดํฉ์ธ, ์ค๊ตญ ๋ฐ๋์ฒด ๋งค์์ธ
MBK ์ํ, ๊ณ ๋ ค์์ฐ ์ง๋ถ ์ถ๊ฐ
๋ฐ๋์ฒด็คพ ๋ฐฐํฐ๋ฆฌ็คพ ์ธ์ ๋ ผ๋, ์ผ๋ณธ ๋ฐ๋์ฒด AI ๋ณด์กฐ๊ธ
ํ๋์ฐจ ์ค๊ตญ ์์จ์ฃผํ ํ๋ ฅ
๋ง์ดํฌ๋ก์คํธ๋ํฐ์ง ๋นํธ์ฝ์ธ ๋๊ท๋ชจ ๋งค์
ํ๊ตญ ์๋ฃAI ๋ฏธ๊ตญ ๋์ , K๋ฐ์ด์ค ๋งค์ถ ๋ฏธ๋ฌ, ๋ฉ๋ํก์ค ์ ๋ฝ ํธ์กฐ, ์คํ๋ก ๋ฐ์ด์ค ์ ๋ฝ ๊ธฐ์ ์ด์
๋์ด ์ ์ฃผ ์๋๊ณ ์ถ๊ฐ ๋น์ฉ
https://naver.me/Fnm9lu8Z
* ํด์ธ ์ํฉ์ ๋งค์ผ ์์นจ ํ๋ฆฌ๋ฏธ์ ์ปจํ ์ธ ๋ฅผ ํตํด ํผ๋ฉ ๋๋ฆฌ๊ณ ์์ต๋๋ค.
* TNBfolio ๋ค์ด๋ฒ ์ปจํ ์ธ ํ๋ฆฌ๋ฏธ์์์ ์ ๊ณตํ๋ ์๋ฃ์ด๋ฉฐ ๋ ์๋ฃ๋ ๊ณ ๊ฐ์ ์ฆ๊ถ ํฌ์ ๊ฒฐ๊ณผ์ ๋ํ ๋ฒ์ ์ฑ ์์์ฌ์ ์ฆ๋น์๋ฃ๋ก ์ฌ์ฉ๋ ์ ์์ต๋๋ค.
๋งํฌ๋ฅผ ํด๋ฆญ ํ์๋ฉด ๊ตฌ๋ ์ ์ฒญ ํ์ค ์ ์์ต๋๋ค.
Naver
11์ 11์ผ ํด์ธ ๋ด์ค
Ardelyx, Inc. (ARDX)
์๊ฐ์ด์ก: 1.50B
๊ตญ๊ฐ: United States
์ฐ์ : #Biotechnology_Pharmaceutical_Preparations
์นํฐ: #Health_Care
ํํ์ด์ง: https://www.ardelyx.com
- ๋ถ๊ธฐ ๋งค์ถ(๊ณต์, ์์ธก, ์ํ, YoY, QoQ)
2412: 116.13M / 108.58M / 7.0% / 238.0% / 18.3%
2409: 98.2M / 86.64M / 13.3% / 74.1% / 34.2%
2406: 73.2M / 55.03M / 33.0% / 227.8% / 59.1%
2403: 46.02M / -- / -- / 304.8% / 33.9%
2312: 34.36M / -- / -- / -- / -39.1%
- ๋ถ๊ธฐ EPS(๊ณต์, ์์ธก, ์ํ, YoY, QoQ)
2412: 0.02 / 0.01 / 100.0% / -- / --
2409: 0.0 / -0.05 / 100.0% / -100.0% / 100.0%
2406: -0.07 / -0.11 / 36.4% / 12.5% / 36.4%
2403: -0.11 / -- / -- / 15.4% / --
2312: -- / -- / -- / -- / --
- ์ฐ๊ฐ ๋งค์ถ(YoY%), EPS(YoY%)
2312: 124.46M(138.6%) / -0.3(28.6%)
2212: 52.16M(416.6%) / -0.42(72.4%)
2112: 10.1M(33.4%) / -1.52(-44.8%)
2012: 7.57M(--) / -1.05(--)
#ARDX
- ์ฌ์ ์์ฝ: Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead...
์๊ฐ์ด์ก: 1.50B
๊ตญ๊ฐ: United States
์ฐ์ : #Biotechnology_Pharmaceutical_Preparations
์นํฐ: #Health_Care
ํํ์ด์ง: https://www.ardelyx.com
- ๋ถ๊ธฐ ๋งค์ถ(๊ณต์, ์์ธก, ์ํ, YoY, QoQ)
2412: 116.13M / 108.58M / 7.0% / 238.0% / 18.3%
2409: 98.2M / 86.64M / 13.3% / 74.1% / 34.2%
2406: 73.2M / 55.03M / 33.0% / 227.8% / 59.1%
2403: 46.02M / -- / -- / 304.8% / 33.9%
2312: 34.36M / -- / -- / -- / -39.1%
- ๋ถ๊ธฐ EPS(๊ณต์, ์์ธก, ์ํ, YoY, QoQ)
2412: 0.02 / 0.01 / 100.0% / -- / --
2409: 0.0 / -0.05 / 100.0% / -100.0% / 100.0%
2406: -0.07 / -0.11 / 36.4% / 12.5% / 36.4%
2403: -0.11 / -- / -- / 15.4% / --
2312: -- / -- / -- / -- / --
- ์ฐ๊ฐ ๋งค์ถ(YoY%), EPS(YoY%)
2312: 124.46M(138.6%) / -0.3(28.6%)
2212: 52.16M(416.6%) / -0.42(72.4%)
2112: 10.1M(33.4%) / -1.52(-44.8%)
2012: 7.57M(--) / -1.05(--)
#ARDX
- ์ฌ์ ์์ฝ: Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead...
Ardelyx, Inc. (ARDX)
์๊ฐ์ด์ก: 1.31B
๊ตญ๊ฐ: United States
์ฐ์ : #Biotechnology_Pharmaceutical_Preparations
์นํฐ: #Health_Care
ํํ์ด์ง: https://www.ardelyx.com
- ๋ถ๊ธฐ ๋งค์ถ(๊ณต์, ์์ธก, ์ํ, YoY, QoQ)
2503: 74.11M / 78.09M / -5.1% / 61.0% / -36.2%
2412: 116.13M / 108.58M / 7.0% / 238.0% / 18.3%
2409: 98.2M / 86.64M / 13.3% / 74.1% / 34.2%
2406: 73.2M / 55.03M / 33.0% / 227.8% / 59.1%
2403: 46.02M / -- / -- / 304.8% / 33.9%
- ๋ถ๊ธฐ EPS(๊ณต์, ์์ธก, ์ํ, YoY, QoQ)
2503: -0.17 / -0.11 / -54.5% / -54.5% / -950.0%
2412: 0.02 / 0.01 / 100.0% / -- / --
2409: 0.0 / -0.05 / 100.0% / -100.0% / 100.0%
2406: -0.07 / -0.11 / 36.4% / 12.5% / 36.4%
2403: -0.11 / -- / -- / 15.4% / --
- ์ฐ๊ฐ ๋งค์ถ(YoY%), EPS(YoY%)
2312: 124.46M(138.6%) / -0.3(28.6%)
2212: 52.16M(416.6%) / -0.42(72.4%)
2112: 10.1M(33.4%) / -1.52(-44.8%)
2012: 7.57M(--) / -1.05(--)
#ARDX
- ์ฌ์ ์์ฝ: Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and intern...
์๊ฐ์ด์ก: 1.31B
๊ตญ๊ฐ: United States
์ฐ์ : #Biotechnology_Pharmaceutical_Preparations
์นํฐ: #Health_Care
ํํ์ด์ง: https://www.ardelyx.com
- ๋ถ๊ธฐ ๋งค์ถ(๊ณต์, ์์ธก, ์ํ, YoY, QoQ)
2503: 74.11M / 78.09M / -5.1% / 61.0% / -36.2%
2412: 116.13M / 108.58M / 7.0% / 238.0% / 18.3%
2409: 98.2M / 86.64M / 13.3% / 74.1% / 34.2%
2406: 73.2M / 55.03M / 33.0% / 227.8% / 59.1%
2403: 46.02M / -- / -- / 304.8% / 33.9%
- ๋ถ๊ธฐ EPS(๊ณต์, ์์ธก, ์ํ, YoY, QoQ)
2503: -0.17 / -0.11 / -54.5% / -54.5% / -950.0%
2412: 0.02 / 0.01 / 100.0% / -- / --
2409: 0.0 / -0.05 / 100.0% / -100.0% / 100.0%
2406: -0.07 / -0.11 / 36.4% / 12.5% / 36.4%
2403: -0.11 / -- / -- / 15.4% / --
- ์ฐ๊ฐ ๋งค์ถ(YoY%), EPS(YoY%)
2312: 124.46M(138.6%) / -0.3(28.6%)
2212: 52.16M(416.6%) / -0.42(72.4%)
2112: 10.1M(33.4%) / -1.52(-44.8%)
2012: 7.57M(--) / -1.05(--)
#ARDX
- ์ฌ์ ์์ฝ: Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and intern...